September 28th, 2016
By Joanne Waldstreicher, M.D., Chief Medical Officer, Johnson & Johnson
As a physician, mother and daughter, I have a keen understanding of the complexities and importance of fair, objective and timely decision-making when it comes to best serving the health and well-being of not only my patients, but also my parents, my siblings and my children.
My personal experiences shape how I lead our team at Johnson & Johnson in responding to the people we serve.
This is especially evident in the way that we manage access to our experimental treatments, known as compassionate use requests. It is paramount that we, as a company involved in research, respond in a timely and objective manner that balances and supports the needs of individuals in urgent need of new treatments with those of the larger patient community and future patients. Our goal, as developers and researchers of new medicines, is to drive the best possible outcomes for patients and their families today and tomorrow.
As I shared last year, Johnson & Johnson’s recognition of the need to fairly and ethically address compassionate use requests led to our partnership with the New York University (NYU) School of Medicine. Together, we instituted a first-of-its-kind pilot program—the Compassionate Use Advisory Committee (CompAC)—designed to effectively address the complex and emotional challenges associated with the use of investigational medicines.